Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Supernus Pharmaceuticals missed estimated earnings by -28.999999999999996%, reporting an EPS of $0.39 versus an estimate of $0.55.
Revenue was down $3.01 million from the same period last year.
Last quarter the company missed on EPS by $0.42 which was followed by a 11.0% increase in the share price the next day.
Here's a look at Supernus Pharmaceuticals's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | 0.13 | -0.23 | 0.17 | 0.68 |
EPS Actual | -0.29 | -0.02 | 0.29 | 0.43 |
Revenue Estimate | 146.14M | 144.38M | 139.02M | 180.37M |
Revenue Actual | 153.88M | 135.56M | 153.76M | 167.33M |
To track all earnings releases for Supernus Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SUPN